CLINICAL COURSE OF COVID-19 PATIENTS UNDER MESENCHYMAL STEM CELL THERAPY

Hayri Canbaz; Hikmet Can Çubukçu; Ahmet Demir; Fatih Kacıroğlu; Seher Taş; Alpay Tuncar; Mehmet Ferit Fedai; Murat Gülşen; Attila Beştemir

Article Details

CLINICAL COURSE OF COVID-19 PATIENTS UNDER MESENCHYMAL STEM CELL THERAPY

Authors:

Hayri Canbaz | Hikmet Can Çubukçu | Ahmet Demir | Fatih Kacıroğlu | Seher Taş | Alpay Tuncar | Mehmet Ferit Fedai | Murat Gülşen | Attila Beştemir

Publisher:

Istanbul University

Main Topics:

Clinical Sciences

Journal:

Journal of Advanced Research in Health Sciences Vol.6 Issue 1, pp.40-45

Document Type:

Article

Publication Date:

2/2023

Document Language:

English

Document ID (Org No.):

2001287077

pISSN:

2651-4060

Keywords:

Abstract:

 Objective: Several countries have used mesenchymal stem cells MSCs in clinical trials for treating Coronavirus-19 COVID-19 patients, considering their therapeutic effects through tissue repair and anti-inflammatory mechanisms. This study aimed to investigate the early effects of MSC application in COVID-19 pneumonia patients on clinical and inflammatory parameters and life expectancy. Material and Method: We retrospectively analyzed 164 unvaccinated patients with COVID-19 pneumonia all age groups who had applied to the Republic of Turkiye, Ministry of Health, Department of Tissue, Organ Transplantation, and Dialysis Services and received the MSC application from March 1, 2020 to March 1, 2021. Results: Using the Kaplan Mayer survival analysis, the cut-off age which significantly increased the survival risk was found to be 61 years. Females had a 1.56 times higher risk of death than males. Sixty-eight percent 113164 of the patients had a comorbidity, which increased the risk of death by 1.58 times compared to those without any comorbidity. The presence of coronary artery disease increased the risk of death by 1.79 times. Further, the risk of death was 7 times higher in intubated patients than in those who were not 95 CI: 3.7213.17. Unfortunately, 64 106164 of the patients died. Lastly, there was a statistically significant increase in the post-MSC treatment median Sequential Organ Failure Assessment Score SOFA score values at the time of application, on days 3, 7, 14, and until the end dischargeexitus. Conclusion: This study was conducted with unvaccinated patients and MSC treatment for COVID-19-related pneumonia is not adequately effective.

 Objective: Several countries have used mesenchymal stem cells MSCs in clinical trials for treating Coronavirus-19 COVID-19 patients, considering their therapeutic effects through tissue repair and anti-inflammatory mechanisms. This study aimed to investigate the early effects of MSC application in COVID-19 pneumonia patients on clinical and inflammatory parameters and life expectancy. Material and Method: We retrospectively analyzed 164 unvaccinated patients with COVID-19 pneumonia all age groups who had applied to the Republic of Turkiye, Ministry of Health, Department of Tissue, Organ Transplantation, and Dialysis Services and received the MSC application from March 1, 2020 to March 1, 2021. Results: Using the Kaplan Mayer survival analysis, the cut-off age which significantly increased the survival risk was found to be 61 years. Females had a 1.56 times higher risk of death than males. Sixty-eight percent 113164 of the patients had a comorbidity, which increased the risk of death by 1.58 times compared to those without any comorbidity. The presence of coronary artery disease increased the risk of death by 1.79 times. Further, the risk of death was 7 times higher in intubated patients than in those who were not 95 CI: 3.7213.17. Unfortunately, 64 106164 of the patients died. Lastly, there was a statistically significant increase in the post-MSC treatment median Sequential Organ Failure Assessment Score SOFA score values at the time of application, on days 3, 7, 14, and until the end dischargeexitus. Conclusion: This study was conducted with unvaccinated patients and MSC treatment for COVID-19-related pneumonia is not adequately effective.

 Objective: Several countries have used mesenchymal stem cells MSCs in clinical trials for treating Coronavirus-19 COVID-19 patients, considering their therapeutic effects through tissue repair and anti-inflammatory mechanisms. This study aimed to investigate the early effects of MSC application in COVID-19 pneumonia patients on clinical and inflammatory parameters and life expectancy. Material and Method: We retrospectively analyzed 164 unvaccinated patients with COVID-19 pneumonia all age groups who had applied to the Republic of Turkiye, Ministry of Health, Department of Tissue, Organ Transplantation, and Dialysis Services and received the MSC application from March 1, 2020 to March 1, 2021. Results: Using the Kaplan Mayer survival analysis, the cut-off age which significantly increased the survival risk was found to be 61 years. Females had a 1.56 times higher risk of death than males. Sixty-eight percent 113164 of the patients had a comorbidity, which increased the risk of death by 1.58 times compared to those without any comorbidity. The presence of coronary artery disease increased the risk of death by 1.79 times. Further, the risk of death was 7 times higher in intubated patients than in those who were not 95 CI: 3.7213.17. Unfortunately, 64 106164 of the patients died. Lastly, there was a statistically significant increase in the post-MSC treatment median Sequential Organ Failure Assessment Score SOFA score values at the time of application, on days 3, 7, 14, and until the end dischargeexitus. Conclusion: This study was conducted with unvaccinated patients and MSC treatment for COVID-19-related pneumonia is not adequately effective.

 Giriş: Birkaç ülke, doku onarımı ve anti-inflamatuar mekanizmalar yoluyla terapötik etkilerini göz önünde bulundurarak, Koronavirüs-19 COVID-19 hastalarını tedavi etmek için klinik deneylerde mezenkimal kök hücreleri MKH kullanmıştır. Bu çalışma, COVID-19 pnömoni hastalarında MKH uygulamasının klinik ve inflamatuar parametreler ve yaşam beklentisi üzerindeki erken etkilerini araştırmak amaçladı. Gereç ve Yöntem: Türkiye Cumhuriyeti Sağlık Bakanlığı Doku, Organ Nakli ve Diyaliz Hizmetleri Daire Başkanlığına başvuran ve 1 Mart 2020 - 1 Mart 2021 tarihleri arasında MKH uygulaması için başvurusu olan COVID-19 pnömonisi tüm yaş grupları olan aşılanmamış 164 hastayı geriye dönük olarak inceledik. Bulgular: Kaplan Mayer sağkalım analizi kullanılarak, kırılım yaşı hayatta kalma riskini önemli ölçüde artıran 61 yıl olarak bulundu. Kadınlar erkeklere göre 1.56 kat daha fazla ölüm riskine sahipti. Hastaların 68inde 113164 komorbidite mevcuttu ve bu komorbiditesi olmayanlara göre ölüm riskini 1,58 kat artırıyordu. Koroner arter hastalığı varlığı ölüm riskini 1,79 kat artırdı. Ayrıca, entübe hastalarda entübe olmayanlara göre ölüm riski 7 kat daha yüksekti 95 GA: 3.72-13.17. Maalesef hastaların 64ü 106164 öldü. Son olarak, MKH sonrası tedavi medyan Sıralı Organ Yetmezliği Değerlendirme Skoru SOFA değerlerinde uygulama sırasında, 3, 7, 14. günlerde ve sonuna kadar taburcuölüm istatistiksel olarak anlamlı bir artış oldu. Sonuç: Bu çalışma aşılanmamış hastalarla yapılmıştır ve COVID-19 ile ilişkili pnömoni için MKH tedavisi yeterince etkili değildir.

Article Details

CLINICAL COURSE OF COVID-19 PATIENTS UNDER MESENCHYMAL STEM CELL THERAPY

Authors:

Hayri Canbaz | Hikmet Can Çubukçu | Ahmet Demir | Fatih Kacıroğlu | Seher Taş | Alpay Tuncar | Mehmet Ferit Fedai | Murat Gülşen | Attila Beştemir

Publisher:

Istanbul University

Main Topics:

Clinical Sciences

Journal:

Journal of Advanced Research in Health Sciences Vol.6 Issue 1, pp.40-45

Document Type:

Article

Publication Date:

2/2023

Document Language:

English

Document ID (Org No.):

2001287077

pISSN:

2651-4060

Coronavirus

COVID-19

mesenchymal stem cell

mortality

survival

Koronavirüs

COVID-19

mezenkimal kök hücre

mortalite

sağ kalım

Issues

Article Details

Authors: Hayri Canbaz | Hikmet Can Çubukçu | Ahmet Demir | Fatih Kacıroğlu | Seher Taş | Alpay Tuncar | Mehmet Ferit Fedai | Murat Gülşen | Attila Beştemir

Publisher: Istanbul University

Main Topics: Clinical Sciences

Journal: Journal of Advanced Research in Health Sciences Vol.6 Issue 1, pp.40-45

Document Type: Article

Publication Date: 2/2023

Document Language: English

Document ID (Org No.): 2001287077

pISSN: 2651-4060

Issues

Authors:

Hayri Canbaz | Hikmet Can Çubukçu | Ahmet Demir | Fatih Kacıroğlu | Seher Taş | Alpay Tuncar | Mehmet Ferit Fedai | Murat Gülşen | Attila Beştemir

Publisher:

Istanbul University

Main Topics:

Clinical Sciences

Journal:

Journal of Advanced Research in Health Sciences Vol.6 Issue 1, pp.40-45

Document Type:

Article

Publication Date:

2/2023

Document Language:

English

Document ID (Org No.):

2001287077

pISSN:

2651-4060